10th Jan 2020 12:09
(Alliance News) - Fusion Antibodies PLC said Friday its Non-Executive Director Alan Mawson purchased 20,000 shares in the company on the transaction on Wednesday.
The company, which specialises in discovering, engineering, and supplying pre-clinical antibodies for use in medicine, said Mawson bought 20,000 shares at a price of 77 pence each, worth GBP15,400.
Following the transaction, Mawson has a direct and indirect interest in 108,988 shares, representing approximately 0.5% of the stock.
Mawson is also a non-executive director of Clarendon Fund managers Ltd and sits on its investment committee, the company said.
Clarendon is the fund manager for Nitech Growth Fund LP which holds 358,850 shares and Viridian Fund LP, which holds 1.8 million shares, the company noted.
At the beginning of December Mawson also bought 20,000 shares for a total payment of GBP15,000.
Fusion Antibodies shares were down 4% in London at 75.35 pence each on Friday.
By Loreta Juodagalvyte; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Fusion Antibodies